Attention-Deficit/Hyperactivity Disorder is a new Decision Resources study that explains why this highly prevalent disorder remains significantly underdiagnosed and undertreated in most of the major pharmaceutical markets, and evaluates the emerging therapies best positioned to capitalize on the untapped opportunities in this indication. Because many physicians are reluctant to diagnose and treat the disorder, the market is wide open to innovative new drugs-particularly effective nonstimulant medications and agents available in more convenient dosing regimens.
Numerous Companies Vie for Leadership in the Growing Market for Long- Acting Psychostimulants
Immediate-release methylphenidate, the current mainstay of ADHD treatment, has a very short half-life and so must be administered every four hours to remain effective, resulting in notoriously low compliance rates. Numerous companies will vie for leadership in the growing market for long-acting reformulations of existing psychostimulants. In August 2000, Alza and McNeil Consumer Healthcare launched Concerta, a 12-hour formulation of methylphenidate, in the U.S. market; within five months, sales of Concerta exceeded $60 million. The drug's market share continues to grow. Other new launches that quickly followed Concerta include Celltech Group's Metadate CD, an eight-hour methylphenidate formulation, and Shire Pharmaceuticals' Adderall XR, a 12-hour formulation of mixed amphetamine salts.
Physicians expect Adderall XR to command a significant share of the drug- treated population that currently takes twice-daily Adderall. Adderall XR's U.S. launch in November 2001, is timely because generic forms of Adderall are expected to reach the U.S. market in 2002. If Shire's marketing campaign to encourage patients to switch to the new product before generic erosion occurs is successful, Adderall XR could attain peak-year major-market sales of $250- 500 million.
A Promising Nonstimulant Alternative
Eli Lilly will likely make significant inroads into the ADHD market with its launch of a nonstimulant alternative, atomoxetine, a highly selective norepinephrine reuptake inhibitor. Most experts interviewed for this study believe that atomoxetine will be less effective in reducing ADHD symptoms than psychostimulants but more effective than current nonstimulant therapies. Its clear advantage will be its status as a noncontrolled substance-a factor that will help propel it to the forefront of second-line therapies. Atomoxetine will be used as a first-line therapy for patients who are unwilling or unable to take stimulants.
Attention-Deficit/Hyperactivity Disorder offers invaluable strategic intelligence for pharmaceutical companies competing in this market. This study is part of Mosaic, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
MAKE YOUR OPINION COUNT - Click Here
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, +1-781-296-2553,